MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION UPHOLD LITE; MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC, FOR PELVIC ORGAN PROLAPSE, TRANSVAGIN

Model Number 831-817

Device Problem Adverse Event Without Identified Device or Use Problem (2993)

Patient Problems Incontinence (1928); Pain (1994); Abnormal Vaginal Discharge (2123); Constipation (3274); Unspecified Mental, Emotional or Behavioural Problem (4430); Dyspareunia (4505); Insufficient Information (4580)

Event Date 05/05/2014

Event Type  Injury  

Manufacturer Narrative

(b)(6).The complainant was unable to provide the suspect device upn and lot number; therefore, the lot expiration and device manufacture dates are unknown.The upn provided was chosen as a representative upn to capture the implanted device.The complainant indicated that the device is not available for return; therefore, a failure analysis of the complaint device could not be completed.If any further relevant information is identified, a supplemental medwatch will be filed.

Event Description

It was reported to boston scientific corporation that a uphold lite implant and a advantage implant were implanted into the patient on (b)(6) 2013.The patient experienced complications, further surgery, and nonsurgical treatment.Patient symptoms include: eep; back pain; vaginal pain; pelvic pain; groin pain; perin pain; anal pain; rect pain; thi pain; pain inter; inab inter; off vag dis; diff bowel; incont not pres; rec incont; damage; psych; oth pain: back of legs.Surgical interventions: on (b)(6) 2014 the patient underwent further surgery regarding the advantage implant/uphold lite implant under general anesthesia for the following purpose: prepare of complications and some mesh removal in areas of protrusion and erosion.On (b)(6) 2017 the patient underwent further surgery regarding the uphold lite implant/advantage implant under general anesthesia for the following purpose: to resolve complications and remove mesh where possible.On (b)(6) 2021 the patient underwent further surgery regarding the uphold lite implant/advantage implant under general anesthesia for the following purpose: botox injections to pelvic floor and vagina to reduce pain.On (b)(6) 2020 the patient underwent further surgery regarding the uphold lite implant/advantage implant under general anesthesia for the following purpose: examination and assessment of pelvic floor, bladder.Nonsurgical treatments: on (b)(6) 2008 the patient commenced pain medication: tramadol for the treatment of: pain management.On (b)(6) 2017 the patient commenced psychological medication: fluoxetine for the treatment of: major depression treatment.On (b)(6) 2013 the patient commenced other medication (please specify): lyrica for the treatment of: pain management.On (b)(6) 2008 the patient commenced physiotherapy treatment (including pelvic floor exercises or training) for the treatment of: difficulty with urination, pelvic floor pain.Treatment duration: 1 year.On (b)(6) 2017 the patient commenced topical treatment (including oestrogen cream): oestrogen for the treatment of: pain and dryness.The patient was treated with other (please specify).On (b)(6) 2017 the patient commenced psychological medication: zuban for the treatment of: major depression treatment.On (b)(6) 2013 the patient commenced physiotherapy treatment (including pelvic floor exercises or training) for the treatment of: pain management for back and legs.On (b)(6) 2020 the patient commenced physiotherapy treatment (including pelvic floor exercises or training) for the treatment of: bowel and bladder incontinence, pelvic floor pain.Treatment duration: 6 months.On (b)(6) 2020 the patient commenced physiotherapy treatment (including pelvic floor exercises or training) for the treatment of: bowel and bladder incontinence, pelvic floor pain.On (b)(6) 2017 the patient commenced other (please specify) for the treatment of: to empty bladder at least 4 times daily.

Event Description

It was reported to boston scientific corporation that a uphold lite implant and a advantage implant were implanted into the patient on (b)(6) 2013.The patient experienced complications, further surgery, and nonsurgical treatment.Patient symptoms include: eep; back pain; vaginal pain; pelvic pain; groin pain; perin pain; anal pain; rect pain; thi pain; pain inter; inab inter; off vag dis; diff bowel; incont not pres; rec incont; damage; psych; oth pain: back of legs.Surgical interventions: on (b)(6) 2014 the patient underwent further surgery regarding the advantage implant/uphold lite implant under general anesthesia for the following purpose: repare of complications and some mesh removal in areas of protrusion and errosion.On (b)(6) 2017 the patient underwent further surgery regarding the uphold lite implant/advantage implant under general anesthesia for the following purpose: to resolve complications and remove mesh where possible.On (b)(6) 2021 the patient underwent further surgery regarding the uphold lite implant/advantage implant under general anesthesia for the following purpose: botox injections to pelvic floor and vagina to reduce pain.On (b)(6) 2020 the patient underwent further surgery regarding the uphold lite implant/advantage implant under general anesthesia for the following purpose: examination and accessment of pelvic floor, blooder.Nonsurgical treatments: on (b)(6) 2008 the patient commenced pain medication: tramadol for the treatment of: pain management.On (b)(6) 2017 the patient commenced psychological medication: fluoxetine for the treatment of: major depression treatment.On (b)(6) 2013 the patient commenced other medication (please specify): lyrica for the treatment of: pain management.On (b)(6) 2008 the patient commenced physiotherapy treatment (including pelvic floor exercises or training) for the treatment of: difficulty with urination, pelvic floor pain.Treatment duration: 1 year.On (b)(6) 2017 the patient commenced topical treatment (including oestrogen cream): oestrogen for the treatment of: pain and dryness.The patient was treated with other (please specify).On (b)(6) 2017 the patient commenced psychological medication: zuban for the treatment of: major deppression treatment.On (b)(6) 2013 the patient commenced physiotherapy treatment (including pelvic floor exercises or training) for the treatment of: pain management for back and legs.On (b)(6) 2020 the patient commenced physiotherapy treatment (including pelvic floor exercises or training) for the treatment of: bowel and bloder incontinence, pelvic floor pain.Treatment duration: 6 months.On (b)(6) 2020 the patient commenced physiotherapy treatment (including pelvic floor exercises or training) for the treatment of: bowel and bloder incontinence, pelvic floor pain.On (b)(6) 2017 the patient commenced other (please specify) for the treatment of: to empty blooder at least 4 times daily.

Manufacturer Narrative

Block a1: (b)(6).Block d4, h4: the complainant was unable to provide the suspect device upn and lot number; therefore, the lot expiration and device manufacture dates are unknown.The upn provided was chosen as a representative upn to capture the implanted device.Block h10: the complainant indicated that the device is not available for return; therefore, a failure analysis of the complaint device could not be completed.If any further relevant information is identified, a supplemental medwatch will be filed.Correction: a previous report for this patient and device has been sent under mfr report # 3005099803-2020-06527.

• Brand Name: UPHOLD LITE
• Type of Device: MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC, FOR PELVIC ORGAN PROLAPSE, TRANSVAGIN
• Manufacturer (Section D): BOSTON SCIENTIFIC CORPORATION; 300 boston scientific way; marlborough MA 01752
• Manufacturer (Section G): BOSTON SCIENTIFIC CORPORATION; 780 brookside drive; spencer IN 47460
• Manufacturer Contact: carole morley ; 300 boston scientific way; marlborough, MA 01752 ; 5086834015
• MDR Report Key: 12930803
• MDR Text Key: 286921474
• Report Number: 3005099803-2021-07364
• Device Sequence Number: 1
• Product Code: OTP
• Combination Product (y/n): N
• Reporter Country Code: AS
• PMA/PMN Number: K122459
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Other,Foreign,Consumer
• Reporter Occupation: Other
• Type of Report: Initial,Followup
• Report Date: 01/25/2022

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Model Number: 831-817
• Device Catalogue Number: 831-817
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: No
• Initial Date Manufacturer Received: 11/10/2021
• Initial Date FDA Received: 12/04/2021
• Supplement Dates Manufacturer Received: 01/07/2022
• Supplement Dates FDA Received: 01/25/2022
• Was Device Evaluated by Manufacturer?: Device Not Returned to Manufacturer
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Required Intervention
• Patient Age: 49 YR
• Patient Sex: Female
• Patient Weight: 88 KG